$REPL
Replimune Group, Inc. Stock $repl

$repl Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000173795322000014 Filed on August 04, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$12.75M	$11.40M	$10.25M
YoY Change	36.38%	29.13%	72.01%
% of Gross Profit
Research & Development	$28.83M	$29.48M	$21.22M
YoY Change	44.88%	58.88%	35.07%
% of Gross Profit
Depreciation & Amortization	$617.0K	$620.0K	$549.0K
YoY Change	15.98%	19.69%	12.04%
% of Gross Profit
Operating Expenses	$41.58M	$40.88M	$31.99M
YoY Change	42.17%	49.29%	44.22%
Operating Profit	-$41.58M	-$40.88M
YoY Change	42.17%	49.29%
Interest Expense	$562.0K	-$209.0K	-$422.0K
YoY Change	-217.82%	-55.15%	-10.21%
% of Operating Profit
Other Income/Expense, Net	-$1.523M	-$1.377M	$714.0K
YoY Change	1310.19%	-2067.14%	-37.91%
Pretax Income	-$43.10M	-$42.25M	-$31.70M
YoY Change	46.83%	54.71%	47.42%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$43.10M	-$42.30M	-$31.70M
YoY Change	46.82%	54.95%	47.42%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.79	-$0.78
Diluted Earnings Per Share	-$0.79	-$0.78	-$603.3K
COMMON SHARES
Basic Shares Outstanding	49.31M shares	54.21M shares	47.21M shares
Diluted Shares Outstanding	54.77M shares	54.21M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$371.8M	$395.1M	$395.7M
YoY Change	-14.68%	-13.8%	-16.93%
Cash & Equivalents	$88.93M	$112.2M	$105.9M
Short-Term Investments	$282.9M	$282.8M	$289.7M
Other Short-Term Assets	$4.981M	$4.040M	$5.267M
YoY Change	-13.01%	23.77%	17.04%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$379.4M	$401.9M	$404.0M
YoY Change	-14.63%	-13.48%	-16.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.910M	$8.267M	$7.933M
YoY Change	10.2%	15.2%	6.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.636M	$1.636M	$1.636M
YoY Change	0.0%	0.0%	2.25%
Total Long-Term Assets	$56.71M	$57.48M	$57.22M
YoY Change	-4.02%	-2.84%	-3.6%
TOTAL ASSETS
Total Short-Term Assets	$379.4M	$401.9M	$404.0M
Total Long-Term Assets	$56.71M	$57.48M	$57.22M
Total Assets	$436.1M	$459.4M	$461.2M
YoY Change	-13.38%	-12.28%	-15.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.996M	$4.482M	$3.732M
YoY Change	26.7%	88.16%	58.47%
Accrued Expenses	$14.43M	$12.20M	$13.14M
YoY Change	43.43%	30.33%	42.85%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.600M	$2.581M	$2.562M
YoY Change	3.01%	2.99%	2.48%
Total Short-Term Liabilities	$23.54M	$20.31M	$20.76M
YoY Change	41.48%	34.99%	42.68%
LONG-TERM LIABILITIES
Long-Term Debt	$24.21M	$24.31M	$24.41M
YoY Change	-1.58%	-1.47%	-1.19%
Other Long-Term Liabilities	$4.280M	$4.541M	$4.801M
YoY Change	-11.24%	-8.78%	-5.86%
Total Long-Term Liabilities	$28.49M	$28.85M	$29.21M
YoY Change	-3.16%	-2.7%	-1.99%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.54M	$20.31M	$20.76M
Total Long-Term Liabilities	$28.49M	$28.85M	$29.21M
Total Liabilities	$52.02M	$49.17M	$49.96M
YoY Change	12.97%	9.99%	12.61%
SHAREHOLDERS EQUITY
Retained Earnings	-$396.6M	-$353.5M	-$311.2M
YoY Change	58.75%	60.33%	61.11%
Common Stock	$50.00K	$49.00K	$47.00K
YoY Change	6.38%	4.26%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$384.1M	$410.3M	$411.2M
YoY Change
Total Liabilities & Shareholders Equity	$436.1M	$459.4M	$461.2M
YoY Change	-13.38%	-12.28%	-15.08%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$43.10M	-$42.30M	-$31.70M
YoY Change	46.82%	54.95%	47.42%
Depreciation, Depletion And Amortization	$617.0K	$620.0K	$549.0K
YoY Change	15.98%	19.69%	12.04%
Cash From Operating Activities	-$33.21M	-$33.46M	-$22.56M
YoY Change	44.64%	82.67%	39.85%
INVESTING ACTIVITIES
Capital Expenditures	-$396.0K	$1.068M	-$1.152M
YoY Change	-7.48%	267.01%	49.61%
Acquisitions
YoY Change
Other Investing Activities	$432.0K	$6.383M	-$3.174M
YoY Change	-104.07%	-76.6%	-97.47%
Cash From Investing Activities	$36.00K	$5.315M	-$4.326M
YoY Change	-100.33%	-80.31%	-96.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$31.04M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.423M	$32.52M	359.0K
YoY Change	545.48%	2803.75%	-53.97%
NET CHANGE
Cash From Operating Activities	-33.21M	-$33.46M	-22.56M
Cash From Investing Activities	36.00K	$5.315M	-4.326M
Cash From Financing Activities	7.423M	$32.52M	359.0K
Net Change In Cash	-25.75M	$6.297M	-26.52M
YoY Change	-21.64%	-37.09%	-81.27%
FREE CASH FLOW
Cash From Operating Activities	-$33.21M	-$33.46M	-$22.56M
Capital Expenditures	-$396.0K	$1.068M	-$1.152M
Free Cash Flow	-$32.81M	-$34.52M	-$21.41M
YoY Change	45.63%	85.56%	39.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q2	dei	Entity Central Index Key EntityCentralIndexKey	0001737953
CY2022Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49306734	shares
CY2022Q2	dei	Amendment Flag AmendmentFlag	false
CY2022Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2022Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q2	dei	Document Type DocumentType	10-Q
CY2022Q2	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q2	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
CY2022Q2	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q2	dei	Entity File Number EntityFileNumber	001-38596
CY2022Q2	dei	Entity Registrant Name EntityRegistrantName	REPLIMUNE GROUP, INC.
CY2022Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2082553
CY2022Q2	dei	Entity Address Address Line1 EntityAddressAddressLine1	500 Unicorn Park
CY2022Q2	dei	Entity Address City Or Town EntityAddressCityOrTown	Woburn
CY2022Q2	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022Q2	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01801
CY2022Q2	dei	City Area Code CityAreaCode	781
CY2022Q2	dei	Local Phone Number LocalPhoneNumber	222-9600
CY2022Q2	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022Q2	dei	Trading Symbol TradingSymbol	REPL
CY2022Q2	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q2	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q2	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022Q2	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2022Q2	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	112245000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	105948000	usd
CY2022Q2	us-gaap	Short Term Investments ShortTermInvestments	282837000	usd
CY2022Q1	us-gaap	Short Term Investments ShortTermInvestments	289707000	usd
CY2022Q2	repl	Research And Development Incentives Receivable Current ResearchAndDevelopmentIncentivesReceivableCurrent	2825000	usd
CY2022Q1	us-gaap	Assets Assets	461192000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4482000	usd
CY2022Q1	repl	Research And Development Incentives Receivable Current ResearchAndDevelopmentIncentivesReceivableCurrent	3055000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4040000	usd
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5267000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	401947000	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	403977000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8267000	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7933000	usd
CY2022Q2	repl	Research And Development Incentives Receivable Noncurrent ResearchAndDevelopmentIncentivesReceivableNoncurrent	821000	usd
CY2022Q1	repl	Research And Development Incentives Receivable Noncurrent ResearchAndDevelopmentIncentivesReceivableNoncurrent	0	usd
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1636000	usd
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1636000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5269000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5552000	usd
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	41487000	usd
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	42094000	usd
CY2022Q2	us-gaap	Assets Assets	459427000	usd
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3732000	usd
CY2022Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	12215000	usd
CY2022Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	13392000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1036000	usd
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1070000	usd
CY2022Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2581000	usd
CY2022Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2562000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	20314000	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	20756000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4541000	usd
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4801000	usd
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	24310000	usd
CY2022Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	24406000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	49165000	usd
CY2022Q1	us-gaap	Liabilities Liabilities	49963000	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49298467	shares
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49298467	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47338660	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47338660	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	49000	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	47000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	763150000	usd
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	723359000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-353457000	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-311204000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	520000	usd
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-973000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	410262000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	411229000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	459427000	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	461192000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29478000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18554000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11398000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8827000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	40876000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	27381000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-40876000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-27381000	usd
CY2022Q2	repl	Research And Development Incentives Income ResearchAndDevelopmentIncentivesIncome	851000	usd
CY2021Q2	repl	Research And Development Incentives Income ResearchAndDevelopmentIncentivesIncome	788000	usd
CY2022Q2	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	343000	usd
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51910331	shares
CY2021Q2	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	92000	usd
CY2022Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	552000	usd
CY2021Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	558000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2019000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-252000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1377000	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	70000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-42253000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27311000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.78
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.78
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54211446	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54211446	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51910331	shares
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-42253000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-27311000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1737000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	224000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-244000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-40000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40760000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27127000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	411229000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	31037000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1737000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-244000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1562000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7194000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-42253000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	410262000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	498728000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	224000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-40000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1173000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6250000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-27311000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	479024000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-42253000	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-27311000	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	7194000	usd
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	6250000	usd
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	620000	usd
CY2021Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	518000	usd
CY2022Q2	repl	Net Amortization Of Premiums And Discounts On Short Term Investments NetAmortizationOfPremiumsAndDiscountsOnShortTermInvestments	-243000	usd
CY2022Q2	repl	Increase Decrease Finance Lease Right Of Use Asset IncreaseDecreaseFinanceLeaseRightOfUseAsset	-607000	usd
CY2021Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18314000	usd
CY2021Q2	repl	Net Amortization Of Premiums And Discounts On Short Term Investments NetAmortizationOfPremiumsAndDiscountsOnShortTermInvestments	-658000	usd
CY2022Q2	repl	Increase Decrease In Research And Development Incentives Receivable IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable	850000	usd
CY2021Q2	repl	Increase Decrease In Research And Development Incentives Receivable IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable	788000	usd
CY2022Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1158000	usd
CY2021Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1228000	usd
CY2022Q2	repl	Increase Decrease Operating Lease Right Of Use Asset IncreaseDecreaseOperatingLeaseRightOfUseAsset	-126000	usd
CY2021Q2	repl	Increase Decrease Operating Lease Right Of Use Asset IncreaseDecreaseOperatingLeaseRightOfUseAsset	-108000	usd
CY2021Q2	repl	Increase Decrease Finance Lease Right Of Use Asset IncreaseDecreaseFinanceLeaseRightOfUseAsset	-607000	usd
CY2022Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	895000	usd
CY2021Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	66000	usd
CY2022Q2	repl	Increase Decrease In Accrued Expenses And Other Current Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities	-1067000	usd
CY2021Q2	repl	Increase Decrease In Accrued Expenses And Other Current Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities	456000	usd
CY2022Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-128000	usd
CY2021Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-106000	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33455000	usd
CY2022Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1068000	usd
CY2021Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	291000	usd
CY2022Q2	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	60617000	usd
CY2021Q2	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	32232000	usd
CY2022Q2	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	67000000	usd
CY2021Q2	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	59515000	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5315000	usd
CY2021Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	26992000	usd
CY2022Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	31037000	usd
CY2021Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022Q2	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	77000	usd
CY2021Q2	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	53000	usd
CY2022Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1562000	usd
CY2021Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1173000	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	32522000	usd
CY2021Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1120000	usd
CY2022Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1915000	usd
CY2021Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	212000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6297000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10010000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	107584000	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	184154000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	113881000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	194164000	usd
CY2022Q2	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	318000	usd
CY2022Q2	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	318000	usd
CY2021Q2	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	39000	usd
CY2022Q2	us-gaap	Nature Of Operations NatureOfOperations	Nature of the business<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Replimune Group, Inc. (the “Company”) is a clinical-stage biotechnology company committed to applying its leading expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through its novel tumor-directed oncolytic immunotherapies. The Company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Replimune Group, Inc., whose predecessor was founded in 2015, is the parent company of its wholly owned, direct and indirect subsidiaries: Replimune Limited (“Replimune UK”); Replimune, Inc. (“Replimune US”); Replimune Securities Corporation; and Replimune (Ireland) Limited.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since its inception, including net losses of $42.3 million and $27.3 million for the three months ended June 30, 2022 and 2021, respectively. In addition, as of June 30, 2022, the Company had an accumulated deficit of $353.5 million. The Company expects to continue to generate operating losses for the foreseeable future. As of the issuance date of these consolidated financial statements, the Company expects that its cash and cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance of these consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the COVID-19 coronavirus</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, a novel strain of coronavirus, which causes the disease known as COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 coronavirus has spread globally. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic and the U.S. government imposed travel restrictions on travel between the United States, Europe and certain other countries. The impact of this pandemic has been, and may continue to be, extensive in many aspects of society, which has resulted, and may continue to result, in significant disruptions to the global economy as well as businesses and capital markets around the world.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is continuing to monitor the global outbreak and spread of COVID-19 and, throughout the pandemic, has implemented measures designed to comply with applicable federal, state and local guidelines, as well as care for our employee's health and well-being. The Company will continue to examine its protocols as the pandemic and health guidance evolves. The COVID-19 pandemic continues to affect the United States and global economies and has affected and may continue to affect the Company's operations and those of third parties on which it relies, including by causing disruptions in our raw material and supply of other materials, the manufacturing of its product candidates and its commercialization processes. However, the extent of these delays is currently unknown and has and will likely continue to vary. In addition, the Company may incur unforeseen costs as a result of disruptions in raw material supplies, clinical product supplies, and preclinical studies or clinical trial delays. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken in an effort to contain it or to potentially treat or continue to vaccinate against COVID-19 and the economic impact on local, regional, national and international markets. The Company continues to actively monitor this situation and the possible effects on its financial condition, liquidity, operations, suppliers, supplies, industry and workforce.</span></div>
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-42300000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-27300000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-353500000	usd
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12728000	usd
CY2022Q2	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition, including, expenses, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19. The Company has made estimates of the impact of COVID-19 within the Company's financial statements and there may be changes to those estimates in future periods.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management evaluates its estimates in light of reasonable changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.</span></div>
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13682000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5415000	usd
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4795000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8267000	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7933000	usd
CY2022Q2	us-gaap	Depreciation Depreciation	620000	usd
CY2021Q2	us-gaap	Depreciation Depreciation	518000	usd
CY2022Q2	repl	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	7591000	usd
CY2022Q1	repl	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	5882000	usd
CY2022Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3016000	usd
CY2022Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	5569000	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	560000	usd
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	621000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1048000	usd
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1320000	usd
CY2022Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	12215000	usd
CY2022Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	13392000	usd
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107782000	usd
CY2020Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	269975000	usd
CY2020Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3084238	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2200000	shares
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7194000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6250000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7194000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6250000	usd
CY2017Q3	repl	Conversion Of Stock Ratio ConversionOfStockRatio	1
CY2018Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5284238	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	125000000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6514334	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.78
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M3D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	30358000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1265509	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	18.08
CY2022Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	124028	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	12.60
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	144256	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	19.82
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7511559	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.01
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y5M19D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	31884000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3645749	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.85
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y3M21D
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	24875000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4144044	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	13.15
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4M9D
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	26859000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.15
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	22.29
CY2022Q2	repl	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue	500000	usd
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8008903	shares
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8008903	shares
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-42253000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27311000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54211446	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54211446	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51910331	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51910331	shares
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.78
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.78
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7909024	shares
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7909024	shares
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	607000	usd
CY2021Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	607000	usd
CY2022Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	552000	usd
CY2021Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	558000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	259000	usd
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	242000	usd
CY2022Q2	us-gaap	Lease Cost LeaseCost	1418000	usd
CY2021Q2	us-gaap	Lease Cost LeaseCost	1407000	usd
CY2022Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	552000	usd
CY2021Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	558000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	777000	usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	1932000	usd
CY2022Q2	repl	Operating And Finance Lease Liability Payments Remainder Of Fiscal Year OperatingAndFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	2709000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1044000	usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	2639000	usd
CY2022Q2	repl	Operating And Finance Lease Liability Payments Due Next Twelve Months OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths	3683000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1053000	usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	2718000	usd
CY2022Q2	repl	Operating And Finance Lease Liability Payments Due Year Two OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo	3771000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1062000	usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	2799000	usd
CY2022Q2	repl	Operating And Finance Lease Liability Payments Due Year Three OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree	3861000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1030000	usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	2883000	usd
CY2022Q2	repl	Operating Finance Lease Liability Payments Due Year Four OperatingFinanceLeaseLiabilityPaymentsDueYearFour	3913000	usd
CY2022Q2	repl	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	2868000	usd
CY2022Q2	repl	Finance Lease Liability To Be Paid After Year Four FinanceLeaseLiabilityToBePaidAfterYearFour	38022000	usd
CY2022Q2	repl	Operating And Finance Lease Liability Payments Due After Year Four OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFour	40890000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7834000	usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	50993000	usd
CY2022Q2	repl	Operating And Finance Lease Liability Payments Due OperatingAndFinanceLeaseLiabilityPaymentsDue	58827000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2257000	usd
CY2022Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	24102000	usd
CY2022Q2	repl	Operating And Finance Lease Liability Undiscounted Excess Amount OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount	26359000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	5577000	usd
CY2022Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	26891000	usd
CY2022Q2	repl	Operating And Finance Lease Liability OperatingAndFinanceLeaseLiability	32468000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5269000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5552000	usd
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	41487000	usd
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	42094000	usd
CY2022Q2	repl	Lease Right Of Use Asset LeaseRightOfUseAsset	46756000	usd
CY2022Q1	repl	Lease Right Of Use Asset LeaseRightOfUseAsset	47646000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1036000	usd
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1070000	usd
CY2022Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2581000	usd
CY2022Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2562000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4541000	usd
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4801000	usd
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	24310000	usd
CY2022Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	24406000	usd
CY2022Q2	repl	Lease Liability LeaseLiability	32468000	usd
CY2022Q1	repl	Lease Liability LeaseLiability	32839000	usd
CY2022Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	261000	usd
CY2021Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	242000	usd
CY2022Q2	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	552000	usd
CY2021Q2	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	558000	usd
CY2022Q2	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	77000	usd
CY2021Q2	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	53000	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y7M6D
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y7M6D
CY2022Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P17Y3M18D
CY2021Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P18Y1M6D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.099
CY2022Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.083
CY2021Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.083
CY2022Q2	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	1631000	usd
CY2022Q1	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	1951000	usd
CY2022Q2	repl	Number Of Operating Geographic Regions NumberOfOperatingGeographicRegions	2	region
CY2022Q2	us-gaap	Noncurrent Assets NoncurrentAssets	8267000	usd
CY2022Q1	us-gaap	Noncurrent Assets NoncurrentAssets	7933000	usd

Files In Submission

Name	View Source	Status
0001737953-22-000014-index-headers.html	Edgar Link	pending
0001737953-22-000014-index.html	Edgar Link	pending
0001737953-22-000014.txt	Edgar Link	pending
0001737953-22-000014-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
repl-20220630.htm	Edgar Link	pending
repl-20220630.xsd	Edgar Link	pending
repl-20220630_cal.xml	Edgar Link	unprocessable
repl-20220630_def.xml	Edgar Link	unprocessable
repl-20220630_htm.xml	Edgar Link	completed
repl-20220630_lab.xml	Edgar Link	unprocessable
repl-20220630_pre.xml	Edgar Link	unprocessable
repl-63022x10qxex311.htm	Edgar Link	pending
repl-63022x10qxex312.htm	Edgar Link	pending
repl-63022x10qxex321.htm	Edgar Link	pending
repl-63022x10qxex322.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REPL
Replimune Group, Inc. Stock $repl

2022 Q3 Form 10-Q Financial Statement

#000173795322000014 Filed on August 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REPL Replimune Group, Inc. Stock $repl

2022 Q3 Form 10-Q Financial Statement

#000173795322000014 Filed on August 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REPL
Replimune Group, Inc. Stock $repl